Status:
COMPLETED
Conjugated Linoleic Acid and Atherosclerosis
Lead Sponsor:
UMC Utrecht
Collaborating Sponsors:
University of Aberdeen
Lipid Nutrition B.V
Conditions:
Atherosclerosis
Eligibility:
All Genders
40-70 years
Phase:
PHASE3
Brief Summary
Rationale: Cis-9, trans-11 conjugated linoleic acid (CLA) can protect against the atherosclerosis development in several animal models. Studies in transgenic mice have shown that mechanisms might invo...
Detailed Description
Rationale: Cis-9, trans-11 conjugated linoleic acid (CLA) can protect against the atherosclerosis development in several animal models. Studies in transgenic mice have shown that mechanisms might invo...
Eligibility Criteria
Inclusion
- Written and signed informed consent
- Healthy men and women
- Between 40-70 years of age
- Body mass index \> 25 kg/m2
Exclusion
- Inability to understand the patient information
- Inability to speak, read and understand the Dutch language
- Indication (BP over 160/90) or using blood pressure lowering drugs
- Indication (total cholesterol \> 8 mmol/l) or using lipid lowering drugs
- Indication (glucose \> 7 mmol/l) or using glucose lowering drugs
- Alcohol abuse (\>21 alcoholic beverages per week)
- Women who are pregnant, lactating or who are planning to become pregnant
- Symptomatic vascular disease
- Use of fish oils (omega 3/6,capsules or oil)
- Use of plant stanols/sterols (margarines like benecol, pro active)
- Use of weight loss supplements
- Receipt of any investigational treatment (drug or device) within 30 days prior to visit 1
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
401 Patients enrolled
Trial Details
Trial ID
NCT00706745
Start Date
June 1 2007
End Date
December 1 2008
Last Update
June 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Julius Center for Health Sciences and Primary Care, UMC Utrecht
Utrecht, Utrecht, Netherlands, 3584 CX